Differential effects of antihypertensive drugs on new-onset diabetes?

Current Hypertension Reports

Volumn 7, Issue 4, 2005, Pages 249-256

  Elliott, William J ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PLACEBO; PROTEINASE INHIBITOR; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CHOICE; EARLY DIAGNOSIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENT DIABETES; META ANALYSIS; METABOLIC DISORDER; MORBIDITY; PRACTICE GUIDELINE; REVIEW; SYSTEMATIC REVIEW;

EID: 24944487294     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0021-4     Document Type: Review

References (50)

1. National High Blood Pressure Education Program Coordinating Committee: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
2. American Diabetes Association: Position Statement Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(Suppl 1):S37-S42.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
4. Elliott WJ: Glucose and cholesterol elevations during thiazide therapy: intention-to-treat vs. actual on-therapy experience. Am J Med 1995, 99:261-269.
5. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002, 359:995-1003.
6. Julius S, Kjeldsen SE, Webert M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004, 363:2022-2031.
7. Padwal R, Laupacis A: Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care 2004, 27:247-255.
8. Luna B, Feinglos MN: Drug-induced hyperglycemia. JAMA 2001, 286:1945-1948.
9. Wilkins R: New drugs for the treatment of hypertension. Ann Intern Med 1959, 50:1-12.
10. Goldner MG, Zarowitz H, Akgun S: Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N Engl J Med 1960, 262:403-405.
11. Gurwitz JH, Bohn RL, Glynn RJ, et al.: Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1992, 118:273-278.
12. Bengtsson C, Blohme G, Lapidus L, et al.: Do antihypertensive drugs precipitate diabetes? BMJ 1984, 289:1495-1497.
13. Skarfors ET, Selinus KI, Lithell HO: Risk factors for developing non-insulin dependent diabetes: a 10-year follow-up of men in Uppsala. BMJ 1991, 303:755-760.
14. Mykkanen L, Kuusisto J, Pyorala K et al.: Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertension 1994, 12:1425-1432.
15. Samuelsson O, Hedner T, Berglund G, et al.: Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial in Goteborg, Sweden. J Hum Hypertension 1994, 8:257-263.
16. Rajala U, Qiao Q, Laakso M, et al.: Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2000, 50:231-239.
17. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000, 342:905-912.
18. Pollare T, Lithell H, Morlin C, et al.: Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertension 1989, 7:551-559.
19. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
20. Huupponen R, Lehtonen A, Vahatalo M: Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol 1992, 43:365-368.
21. Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy evaluation (ALPINE Study). J Hypertension 2003, 21:1563-1574.
22. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. The CHARM Investigators and Committees. Lancet 2003, 362:759-766.
23. Lithell H, Hansson L, Skoog L et al.: The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertension 2003, 21:875-886.
24. Sackett DL, Rosenberg WMC, Muir Gray JA, et al.: Evidence based medicine: what it is and what it isn't (editorial). BMJ 1996, 312:71-72.
25. Fletcher A, Amery A, Birkenhager W, et al.: Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertension 1991, 9:225-230.
26. Wilhelmsen L, Berglund G, Elmfeldt D, et al.: Beta-blockers versus diuretics in hypertensive men: main result from the HAPPHY trial. J Hypertension 1987, 5:560-572.
27. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
28. The SHEP Cooperative Study Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991, 265:3255-3264.
29. Medical Research Council Working Party: MRC Trial of treatment of mild hypertension: Principal results. Br Med J (Clin Res) 1985, 291:97-104.
30. Medical Research Council Working Party: Medical Research Council Trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412.
31. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
32. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. The INVEST Investigators. JAMA 2003, 290:2805-2816.
33. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study. The Nordic Diltiazem Study Group. Lancet 2000, 356:359-365.
34. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
35. HOPE Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: The HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Lancet 2000, 355:253-259.
36. The PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058-2068.
37. Vermes E, Ducharme A, Bourassa MG, et al.: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD). Studies of Left Ventricular Dysfunction. Circulation 2003, 107:1291-1296.
38. Svensson P, de Faire U, Sleight P, et al.: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001, 38:E28-E32.
39. Coutinho M, Gerstein HC, Wang Y, et al.: The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
40. Henry P, Thomas F, Benetos A, et al.: Impaired fasting glucose, blood pressure, and cardiovascular disease mortality. Hypertension 2002, 40:458-463.
41. Elliott WJ: ALLHAT: the largest and most important clinical trial in hypertension ever done in the U.S.A. (editorial). Am J Hypertension 1996, 9:409-411.
42. Messerli FH, Weber MA: ALLHAT - All hit or all miss? Key questions still remain (editorial). Am J Cardiol 2003, 92:280-281.
43. Qiao Q, Jousilahti P, Eriksson J, et al.: Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003, 26:2910-2914.
44. Eberly LE, Cohen JD, Prineas R, et al.: Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: The Multiple Risk Factor Intervention Trial experience. Diabetes Care 2003, 26:848-854.
45. Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
46. American Diabetes Association: Hypertension management in adults with diabetes. Diabetes Care 2004, 27(Suppl1): S65-S67.
47. Grundy SM, Cleeman JI, Merz NB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110:227-239.
48. Colhoun H, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
49. American Diabetes Association and the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes of Health: Prevention or delay of type 2 diabetes. Diabetes Care 2004, 27(Suppl1):S47-S54.
50. Lumley T: Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.